Non-Animal Navigator™: Expert strategy and AI-enabled biosimulation to reduce, refine, or replace animal studies
サターラのNon-Animal Navigator™ソリューションは、企業が最適なNAM戦略を選択し最適化できるよう支援します。
Danielle Pillsbury2025年4月30日
Certara Announces Second Annual Certainty U.S. Event
Certara’s premier client conference explores how in-silico methods and biosimulation at scale derisk every stage…
Certara2025年4月22日
In case you missed it: CHI + Certara Webinar on Artificial Intelligence (AI) -Powered Model-Informed Drug Development (MIDD)
2025年4月18日 What’s next for drug development? Recapping our MIDD in the age of…
Certara2025年4月18日
Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing
New offering provides strategic guidance and AI-enabled biosimulation to navigate FDA’s Roadmap to Reducing Animal…
Simona Colucci2025年4月14日
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study
The IMPAACT 2017/MOCHA study, a phase 1/2 multicenter trial across five countries, assessed the safety,…
Danielle Pillsbury2025年3月20日
MIDD in Japan – Implementations, challenges and opportunities
In Japan, there has been a growing adoption of Model Informed Drug Development (MIDD) approaches…
Danielle Pillsbury2025年3月12日
Model-Informed Drug Development in the Age of AI
Lorem ipsum dolor sit amet consectetur. Donec diam risus volutpat tempor. Massa accumsan aliquam nibh…
Danielle Pillsbury2025年3月10日
Postmarketing Assessment of Antibody–Drug Conjugates: Proof-of-Concept Using Model-Based Meta-Analysis and a Clinical Utility Index Approach
This study explores a model-based meta-analysis (MBMA) and a clinical utility index (CUI) approach to…
Danielle Pillsbury2025年3月4日
